Anzeige
Mehr »
Login
Freitag, 23.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Ist das das Einstiegssignal vor der erneuten Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ABG7 | ISIN: SE0007692850 | Ticker-Symbol: 7CA
Tradegate
22.02.24
15:04 Uhr
40,020 Euro
+0,080
+0,20 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CAMURUS AB Chart 1 Jahr
5-Tage-Chart
CAMURUS AB 5-Tage-Chart
RealtimeGeldBriefZeit
39,28040,08022.02.
39,78040,08022.02.

Aktuelle News zur CAMURUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.02.CAMURUS AB: Camurus' Full Year Report 202314
13.02.CAMURUS AB: Camurus appoints Behshad Sheldon as President of Camurus Inc.1
31.01.CAMURUS AB: Change in number of shares and votes in Camurus3
29.12.23CAMURUS AB: Change in number of shares and votes in Camurus2
21.12.23CAMURUS AB: Camurus submits New Drug Application to the US FDA for Oclaiz for treatment of acromegaly5
20.12.23CAMURUS AB: Camurus to enter Large Cap segment on Nasdaq Stockholm3
14.12.23CAMURUS AB: Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors2
09.11.23CAMURUS AB: Camurus' Interim Report Third Quarter 20235
01.11.23CAMURUS AB: Camurus to present at Jefferies 2023 Healthcare Conference London1
23.10.23CAMURUS AB: Camurus raises financial guidance for the full year 20236
18.10.23CAMURUS AB: Camurus' Nomination Committee appointed for the Annual General Meeting 20241
26.09.23CAMURUS AB: Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund2
21.09.23DelveInsight Business Research, LLP: Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG815The increase in the chronic lower back pain market size is a direct consequence of the expected launch of potential therapies, along with great competition among various companies and precision...
► Artikel lesen
05.09.23CAMURUS AB: Camurus announces US launch of Brixadi for the treatment of moderate to severe opioid use disorder by Braeburn1
31.08.23CAMURUS AB: Change in number of shares and votes in Camurus1
17.07.23Camurus AB: Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly430Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient...
► Artikel lesen
24.05.23Camurus AB: Camurus announces FDA approval of Brixadi for the treatment of moderate to severe opioid use disorder536Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosingThree million people in the US diagnosed with opioid use disorderLUND, Sweden, May 24,...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1